tirzepatide trial obesity without diabetes for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Tirzepatide vs semaglutide: A new
Description
No Insurance Reimbursement
Gallbladder-related adverse events, including cholelithiasis and cholecystitis, are uncommon with tirzepatide therapy
When compared to Naltrexone/Bupropion combinations, the survival curves showed sustained separation throughout the observation period, with the most pronounced associations observed for oculomotor binocular dysfunction (HR 0.31, 95% CI: 0.160.60, p = 2.3 10 4 ), cataracts (HR 0.46, 95% CI: 0.230.92, p = 0.025), visual issues and blindness (HR 0.44, 95% CI: 0.260.76, p = 0.003), dry eye disease (HR 0.33, 95% CI: 0.150.71, p = 0.003), ametropic accommodative dysfunction (HR 0.31, 95% CI: 0.160.62, p = 4.3 10 4 ), and visual disturbances (HR 0.46, 95% CI: 0.260.83, p = 0.008)
semaglutide can lead to treatment discontinuation in some patients, particularly with the higher dose of tirzepatide
Early customers describe founders personally answering questions and resolving issues same-day
